CTI BIOPHARMA CORP - FORM 10-K - EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - February 16, 2011

Attached files

file filename
10-K - FORM 10-K - CTI BIOPHARMA CORPd10k.htm
EX-32 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER - CTI BIOPHARMA CORPdex32.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm
EX-23.2 - CONSENT OF MARCUM LLP - CTI BIOPHARMA CORPdex232.htm
EX-23.1 - CONSENT OF STONEFIELD JOSEPHSON, INC. - CTI BIOPHARMA CORPdex231.htm
EX-12.1 - STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES - CTI BIOPHARMA CORPdex121.htm
EX-10.24 - FORM OF AMENDMENT TO AMENDMENT TO EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT - CTI BIOPHARMA CORPdex1024.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm
EX-21.1 4 dex211.htm SUBSIDIARIES OF THE REGISTRANT Subsidiaries of the Registrant

Exhibit 21.1

Subsidiaries of Cell Therapeutics, Inc.

Aequus Biopharma, Inc., a Washington Corporation, CTI Commercial, LLC, a Nevada Limited Liability Company, Systems Medicine, LLC, a Delaware Limited Liability Company and CTI Life Sciences Ltd, a U.K. Limited Company.

The above paragraph includes all subsidiaries of Cell Therapeutics, Inc.

Stock widget

Investing forum

CTI BIOPHARMA CORP Reports

Also read